Abstract 231P
Background
Overall survival (OS) is the optimal marker of efficacy for evaluation of treatments in randomized clinical trials (RCTs) but can take a considerable amount of time to mature. Evaluation of changes in tumor size through objective response rate (ORR) and progression free survival (PFS) has served as an early surrogate of OS however they are imperfect. Time to deterioration (TTD) in quality of life (QoL) measures could act as an early alternative patient centered surrogate of OS.
Methods
We utilised published phase 3 RCTs in solid malignancies that reported OS, PFS, ORR, and time to deterioration (TTD) evaluations of overall QoL or physical function (PF) published between 1st of January 2010 and 30th of June 2022. Weighted regression analysis was utilised to assess the relationship between PFS, ORR ratio, TTD QoL and TTD PF with OS. The coefficient of determination (R2) was used to quantify surrogacy.
Results
After identifying 9109 publications, 138 studies with 86199 patients were included for analysis. 47 RCT involved immunotherapy (IO) whilst 91 investigated non-IO agents. PFS (R2= 0.19) and ORR (R2= 0.05) were poor surrogates of OS. TTD QoL and TTD PF was available in 137 and 75 RCTs respectively. In the respected subset of studies, TTD QoL (TTD QoL R2= 0.18 vs. PFS R2= 0.19) and TTD PF (TTD PF R2= 0.10 vs PFS R2= 0.09) performed similarly to PFS as surrogates of OS. However, for IO agents, TTD PF (R2= 0.38) had a higher surrogacy to OS compared to PFS (R2= 0.19). Furthermore, combining PFS and TTD PF enabled improved prediction of OS (R2= 0.57). Importantly, TTD PF and PFS were not correlated with each other (R2= 0). TTD PF was not a surrogate endpoint of OS for non-IO trials.
Conclusions
Our trial level analysis identified TTD in PF as a potential marker of early OS in trials that utilized IO agents. It could potentially be used in conjunction with PFS to improve surrogacy in specific tumor types. Our results are based on published results and should be validated using patient-level data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts
Presenter: Yanjun Xu
Session: Poster session 01
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01